Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC drug/cosmetics national uniformity Senate floor debate set for July 28.

This article was originally published in The Tan Sheet

Executive Summary

OTC/COSMETICS NATIONAL UNIFORMITY BACKED BY TWO FORMER FDA COMMISSIONERS, Arthur Hull Hayes, MD, and Charles Edwards, MD, in July 23 and July 21 letters to Senate Labor & Human Resources Chairman James Jeffords (R-Vt.). Both letters emphasize that language in the OTC and cosmetics national uniformity clause of Jefford's FDA reform bill (S 830) already allows states to petition for exemption from a national standard. Edwards writes that "national uniformity should play a greater role in FDA-state relations." He points out, however, that "valid and growing state interests also must be recognized" and that S 830 accommodates these concerns.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel